ImmunityBio’s (IBRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research report released on Thursday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

Other equities research analysts have also recently issued reports about the company. BTIG Research started coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 target price for the company. HC Wainwright started coverage on ImmunityBio in a report on Thursday, March 6th. They issued a “buy” rating and a $8.00 target price for the company. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $12.19.

ImmunityBio Trading Down 1.0 %

Shares of IBRX stock opened at $2.87 on Thursday. ImmunityBio has a twelve month low of $2.28 and a twelve month high of $10.53. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -3.12 and a beta of 0.82. The stock has a fifty day simple moving average of $3.08 and a two-hundred day simple moving average of $3.66.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $8.74 million. Research analysts predict that ImmunityBio will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On ImmunityBio

A number of hedge funds have recently made changes to their positions in IBRX. Stephens Inc. AR purchased a new stake in shares of ImmunityBio during the 4th quarter worth $26,000. Cibc World Markets Corp purchased a new stake in ImmunityBio in the fourth quarter valued at about $35,000. Maia Wealth LLC purchased a new stake in ImmunityBio in the fourth quarter valued at about $37,000. GF Fund Management CO. LTD. purchased a new stake in ImmunityBio in the fourth quarter valued at about $37,000. Finally, Schechter Investment Advisors LLC purchased a new stake in ImmunityBio in the fourth quarter valued at about $38,000. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.